Kidney Neoplasms: Tumors or cancers of the KIDNEY.Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Von Hippel-Lindau Tumor Suppressor Protein: A ubiquitin-protein ligase that mediates OXYGEN-dependent polyubiquitination of HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT. It is inactivated in VON HIPPEL-LINDAU SYNDROME.Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.von Hippel-Lindau Disease: An autosomal dominant disorder caused by mutations in a tumor suppressor gene. This syndrome is characterized by abnormal growth of small blood vessels leading to a host of neoplasms. They include HEMANGIOBLASTOMA in the RETINA; CEREBELLUM; and SPINAL CORD; PHEOCHROMOCYTOMA; pancreatic tumors; and renal cell carcinoma (see CARCINOMA, RENAL CELL). Common clinical signs include HYPERTENSION and neurological dysfunctions.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Cell Line, Tumor: A cell line derived from cultured tumor cells.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Nephrectomy: Excision of kidney.Liver Neoplasms: Tumors or cancer of the LIVER.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Angiomatosis: A condition with multiple tumor-like lesions caused either by congenital or developmental malformations of BLOOD VESSELS, or reactive vascular proliferations, such as in bacillary angiomatosis. Angiomatosis is considered non-neoplastic.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Ligases: A class of enzymes that catalyze the formation of a bond between two substrate molecules, coupled with the hydrolysis of a pyrophosphate bond in ATP or a similar energy donor. (Dorland, 28th ed) EC 6.Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Ubiquitin-Protein Ligases: A diverse class of enzymes that interact with UBIQUITIN-CONJUGATING ENZYMES and ubiquitination-specific protein substrates. Each member of this enzyme group has its own distinct specificity for a substrate and ubiquitin-conjugating enzyme. Ubiquitin-protein ligases exist as both monomeric proteins multiprotein complexes.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Cucurbitacins: Triterpenes that derive from LANOSTEROL by a shift of the C19 methyl to the C9 position. They are found in seeds and roots of CUCURBITACEAE and other plants and are noted for intense bitterness.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Secosteroids: Steroids in which fission of one or more ring structures and concomitant addition of a hydrogen atom at each terminal group has occurred.Lung Neoplasms: Tumors or cancer of the LUNG.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Hypoxia-Inducible Factor 1, alpha Subunit: Hypoxia-inducible factor 1, alpha subunit is a basic helix-loop-helix transcription factor that is regulated by OXYGEN availability and is targeted for degradation by VHL TUMOR SUPPRESSOR PROTEIN.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Chromosomes, Human, Pair 3: A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Hemangiosarcoma: A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed)Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.DNA, Neoplasm: DNA present in neoplastic tissue.Hypoxia-Inducible Factor 1: A basic helix-loop-helix transcription factor that plays a role in APOPTOSIS. It is composed of two subunits: ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR and HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT.Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Proto-Oncogene Proteins c-met: Cell surface protein-tyrosine kinase receptors for HEPATOCYTE GROWTH FACTOR. They consist of an extracellular alpha chain which is disulfide-linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and sites critical for the regulation of kinase activity. Mutations of the gene for PROTO-ONCOGENE PROTEINS C-MET are associated with papillary renal carcinoma and other neoplasia.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Breast Neoplasms: Tumors or cancer of the human BREAST.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Transplantation, Heterologous: Transplantation between animals of different species.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Benzenesulfonates: Organic salts and esters of benzenesulfonic acid.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Kidney: Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.RNA, Neoplasm: RNA present in neoplastic tissue.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Basic Helix-Loop-Helix Transcription Factors: A family of DNA-binding transcription factors that contain a basic HELIX-LOOP-HELIX MOTIF.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Phenylurea Compounds: Compounds that include the amino-N-phenylamide structure.Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Proteins: Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.Mouth Neoplasms: Tumors or cancer of the MOUTH.Niacinamide: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.Vascular Endothelial Growth Factor A: The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.Mice, Inbred BALB CPolycythemia: An increase in the total red cell mass of the blood. (Dorland, 27th ed)Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Colonic Neoplasms: Tumors or cancer of the COLON.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Neoplastic Syndromes, Hereditary: The condition of a pattern of malignancies within a family, but not every individual's necessarily having the same neoplasm. Characteristically the tumor tends to occur at an earlier than average age, individuals may have more than one primary tumor, the tumors may be multicentric, usually more than 25 percent of the individuals in direct lineal descent from the proband are affected, and the cancer predisposition in these families behaves as an autosomal dominant trait with about 60 percent penetrance.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Interferon-alpha: One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.Cell Hypoxia: A condition of decreased oxygen content at the cellular level.Stomach Neoplasms: Tumors or cancer of the STOMACH.Skin Neoplasms: Tumors or cancer of the SKIN.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Nuclear Proteins: Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Cerebellar Neoplasms: Primary or metastatic neoplasms of the CEREBELLUM. Tumors in this location frequently present with ATAXIA or signs of INTRACRANIAL HYPERTENSION due to obstruction of the fourth ventricle. Common primary cerebellar tumors include fibrillary ASTROCYTOMA and cerebellar HEMANGIOBLASTOMA. The cerebellum is a relatively common site for tumor metastases from the lung, breast, and other distant organs. (From Okazaki & Scheithauer, Atlas of Neuropathology, 1988, p86 and p141)Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Vascular Endothelial Growth Factors: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Endothelial Growth Factors: These growth factors are soluble mitogens secreted by a variety of organs. The factors are a mixture of two single chain polypeptides which have affinity to heparin. Their molecular weight are organ and species dependent. They have mitogenic and chemotactic effects and can stimulate endothelial cells to grow and synthesize DNA. The factors are related to both the basic and acidic FIBROBLAST GROWTH FACTORS but have different amino acid sequences.Angiogenesis Inhibitors: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Interleukin-2: A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)DNA-Binding Proteins: Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.Cell Cycle: The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Lymphokines: Soluble protein factors generated by activated lymphocytes that affect other cells, primarily those involved in cellular immunity.Up-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Pyrroles: Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Tongue Neoplasms: Tumors or cancer of the TONGUE.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.DNA, Complementary: Single-stranded complementary DNA synthesized from an RNA template by the action of RNA-dependent DNA polymerase. cDNA (i.e., complementary DNA, not circular DNA, not C-DNA) is used in a variety of molecular cloning experiments as well as serving as a specific hybridization probe.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Recombinant Fusion Proteins: Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.Transcription, Genetic: The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Phosphorylation: The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Genes, p53: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Codon: A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE).Adenoma: A benign epithelial tumor with a glandular organization.Chemoembolization, Therapeutic: Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Chromosome Mapping: Any method used for determining the location of and relative distances between genes on a chromosome.Carcinoma, Basosquamous: A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Thyroidectomy: Surgical removal of the thyroid gland. (Dorland, 28th ed)Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Interferon-gamma: The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Cadherins: Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Papillomaviridae: A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.Rectal Neoplasms: Tumors or cancer of the RECTUM.Adenocarcinoma, Bronchiolo-Alveolar: A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Urothelium: The epithelial lining of the URINARY TRACT.
... tumor, Renal cell carcinoma. ...
Chromophobe renal carcinoma and hybrid oncocytic tumors with features of chromophobe renal carcinoma and renal oncocytoma, ... September 2014). "The somatic genomic landscape of chromophobe renal cell carcinoma". Cancer Cell. 26 (3): 319-30. doi:10.1016/ ... April 2007). "Identification and characterization of Birt-Hogg-Dubé associated renal carcinoma". The Journal of Pathology. 211 ... Armah HB, Parwani AV (January 2010). "Xp11.2 translocation renal cell carcinoma". Archives of Pathology & Laboratory Medicine. ...
Malignancy, e.g. renal cell carcinoma. Placement of topical tetracycline in a petrolatum base into a surgical site. The ... Oct 2000). "Myospherulosis in renal cell carcinoma". Arch Pathol Lab Med. 124 (10): 1476-9. doi:10.1043/0003-9985(2000)124. 2.0 ...
Clear cell renal carcinoma: del 9p and del 14q are poor prognostic indicators. Papillary renal cell carcinoma: duplication of ... Clear cell carcinoma: loss of 3p Papillary carcinoma: trisomy 7 and 17 Chromophobe carcinoma: hypodiploid with loss of ... van den Berg, E; Störkel, S (2003). "Kidney: Clear cell renal cell carcinoma". Atlas Genet Cytogenet Oncol Haematol. 7 (3): 424 ... "Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma". Modern pathology ...
... the renal tubule and the renal pelvis. Most cancers in the renal tubule are renal cell carcinoma and clear cell adenocarcinoma ... In addition to renal cell carcinoma and renal pelvis carcinoma, other, less common types of kidney cancer include: Squamous ... The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) (also known as ... "Kidney Cancer (Adult) - Renal Cell Carcinoma" (PDF). American Cancer Society. Last Revised: May 16, 2016 "Commonly Used Pain ...
Lipworth L, Tarone RE, McLaughlin JK (Dec 2006). "The epidemiology of renal cell carcinoma". The Journal of Urology. 176 (6 Pt ... In addition to increasing the risk of kidney cancer, smoking can also contribute to additional renal damage. Smokers are at a ... Doll R, Hill AB (Sep 1950). "Smoking and carcinoma of the lung; preliminary report". British Medical Journal. 2 (4682): 739-748 ... "Smoking and Carcinoma of the Lung" which appeared in the British Medical Journal. This paper reported that "heavy smokers were ...
It is investigational agent in clinical trials for renal cell carcinoma. Its development was suspended as a "naked" or ... Bedke J, Stenzl A (2013). "Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?". Expert ... It was granted fast track status and orphan drug designation by the FDA for renal cancer. In January 2017, Telix ... CAIX is expressed on the surface of most renal cancer cells and is hypothesized to be on the surface of other tumor cells. ...
ISBN 978-0-19-157556-3. Wah, T.M. (2017). "Image-guided ablation of renal cell carcinoma". Clinical radiology. Elsevier BV. 72 ... This technique is mostly used for the treatment of small renal cancers and for the palliation of painful bone lesions. ...
"Immunotherapy in Metastatic Renal Cell Carcinoma" (PDF). "Landmarks in the diagnosis and treatment of renal cell carcinoma". ... The Many Faces of Renal Cell Carcinoma". Rev Urol. 4: 163-70. PMC 1475999 . PMID 16985675. "Tubulocystic Renal Cell Carcinoma: ... "Kidney Cancer (Adult) - Renal Cell Carcinoma + - Text Size Download Printable Version [PDF]» Early Detection, Diagnosis, and ... "Localized renal cell carcinoma management: an update". Retrieved 6 September 2016. "Kidney Cancer Resources". Retrieved 6 ...
IL-2 has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma and metastatic ... Various mutations in the MET gene are associated with papillary renal carcinoma. MET proto-oncogene (GeneID: 4233) has a total ... Foretinib has completed a phase 2 clinical trials with indications for papillary renal cell carcinoma, gastric cancer, and head ... Dharmawardana PG, Giubellino A, Bottaro DP (2004). "Hereditary papillary renal carcinoma type I". Curr. Mol. Med. 4 (8): 855-68 ...
Disrupted in renal carcinoma 2 is a protein that in humans is encoded by the DIRC2 gene. This gene encodes a membrane-bound ... Disruption of this gene by translocation has been associated with haplo-insufficiency and renal cell carcinomas. GRCh38: ... Disrupted in renal carcinoma 2". Savalas LR, Gasnier B, Damme M, Lübke T, Wrocklage C, Debacker C, Jézégou A, Reinheckel T, ... by a familial renal cell carcinoma-associated t(2;3)(q35;q21)". Human Molecular Genetics. 11 (6): 641-9. doi:10.1093/hmg/11.6. ...
In 2007, mTORC1 inhibitors began being approved for treatments against cancers such as renal cell carcinoma. In 2008 they were ... Voss MH, Molina AM, Motzer RJ (Aug 2011). "mTOR inhibitors in advanced renal cell carcinoma". Hematology/oncology Clinics of ...
Renal Cell Carcinoma)? Vera-Badillo, Francisco Emilio, Esther Conde, and Ignacio Duran. "Chromophobe Renal Cell Carcinoma: A ... While renal cell carcinoma is one of the most frequently diagnosed cancers, chromophobe renal cancer only accounts for five ... also refers to a type of renal cell carcinoma (distinct from "clear cell"). Chromophobe renal cancer is part of a rare, genetic ... Furthermore, 30% of patients with Birt-Hogg-Dubé syndrome will also develop chromophobe renal cancer. One of the only ...
In some cases the renal cell carcinoma may be a manifestation of an undiagnosed hereditary leiomyomatosis and renal cell cancer ... Altman D, Yin L, Johansson A, Lundholm C, Grönberg H (2010). "Risk of Renal Cell Carcinoma After Hysterectomy". Archives of ... Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (1999). "Increased risk of renal cell carcinoma subsequent to ... Hysterectomy may cause an increased risk of the relatively rare renal cell carcinoma. The increased risk is particularly ...
Renal cell carcinoma. Under-expression. 100%. Western (protein) blotting and mRNA. . ... "Increased expression of SET domain containing proteins and decreased expression of Rad51 in different renal cell carcinomas". ... Klopfleisch R, Schütze M, Gruber AD (Jan 2010). "RAD51 protein expression is increased in canine mammary carcinomas". ... "Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas". Int. J. Cancer. 88 (1): 28-36. ...
1995). "Hereditary papillary renal cell carcinoma: clinical studies in 10 families". J. Urol. 153 (3 Pt 2): 907-12. doi:10.1016 ... In a subset of papillary renal cell carcinomas, a t(X;1)(p11;q21) chromosome translocation has been repeatedly reported and is ... Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993). "Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic ... 2001). "PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors". ...
... is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is ... "Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma". The New England Journal of Medicine. 373 (19): 1814-23. doi: ... form is used to treat medullary thyroid cancer and a tablet form is used as a second line treatment for renal cell carcinoma. ... Exelixis' Phase III trial results of testing the drug in renal cancer published in the NEJM in 2015. In April 2016 the FDA ...
Hematuria Hyposthenuria Renal medullary carcinoma, a cancer affecting the kidney, is a very rare complication seen in patients ... Davis, Charles J.; Mostofi, F. K.; Sesterhenn, Isabell A. (1995). "Renal Medullary Carcinoma The Seventh Sickle Cell ... Renal papillary necrosis (only considered "possible" by some sources) Splenic infarcts at high altitude. Surgery may not always ... Zadeii, Gino; Lohr James W. (1997). "Renal Papillary Necrosis in a Patient with Sickle Cell Trait". Journal of the American ...
Targeted therapy for the treatment of advanced renal cell carcinoma Immunotherapy Combinations for Renal Cell Carcinoma Offer ... implications for patients with advanced renal cell carcinoma Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma ... Everolimus for renal cell carcinoma: predictive factors for response and future directions. Medical Oncology Supplement. 2008. ... In: Renal Cell Carcinoma: Molecular Targets and Clinical Applications. Humana Press. 2007. Contemporary Therapeutic Strategies ...
4 July 2013). "Comprehensive molecular characterization of clear cell renal cell carcinoma". Nature. 499 (7456): 43-9. doi: ... "Integrated genomic characterization of endometrial carcinoma". Nature. 497 (7447): 67-73. doi:10.1038/nature12113. PMID ...
Pazopanib was approved for renal cell carcinoma in 2009. Regorafenib was approved for colorectal cancer in Sept 2012. Holmes K ...
1997). "Renal cell carcinoma and normal kidney protein expression". Electrophoresis. 18 (3-4): 599-604. doi:10.1002/elps. ... 2003). "CA125 and UQCRFS1 FISH studies of ovarian carcinoma". Gynecol. Oncol. 90 (1): 29-36. doi:10.1016/S0090-8258(03)00144-6 ...
2008). "Germline SDHB mutations and familial renal cell carcinoma". J. Natl. Cancer Inst. 100 (17): 1260-2. doi:10.1093/jnci/ ...
The symptoms and signs resolve if the renal cell carcinoma (or another associated tumor) is successfully ablated. It is due to ... Reversible hepatic dysfunction in renal cell carcinoma (author's transl)]". Wien Klin Wochenschr. 90 (8): 268-70. PMID 636440. ... syndrome is a constellation of signs and symptoms of liver dysfunction that arise due to presence of renal cell carcinoma, and ...
The suggested role for this protein is in tumorigenesis of renal cell carcinoma. Two alternatively spliced transcript variants ... 2005). "Pathological characterization of Kank in renal cell carcinoma". Exp. Mol. Pathol. 78 (1): 41-8. doi:10.1016/j.yexmp. ... located at 9p24 is a growth suppressor of renal cell carcinoma". J Biol Chem. 277 (39): 36585-91. doi:10.1074/jbc.M204244200. ...
Expression of PAX8 is increased in neoplastic renal tissues, Wilms tumors, ovarian cancer and Müllerian carcinomas. For this ... and endometrial carcinomas. The mechanism of switching on the genes is unknown. Some studies have suggested that the renal ... almost all subtypes of renal cell carcinoma, nephrogenic adenomas, ovarian cancer cells, bladder, prostate, ... is implicated in some follicular thyroid carcinomas and follicular-variant papillary thyroid carcinoma. The mechanism for ...
We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma ... "We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma ... We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma ... We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. Renal cell carcinoma ...
Targeting renal cell carcinoma with a HIF-2 antagonist.. Chen W1,2,3, Hill H1,2, Christie A1, Kim MS1,4, Holloman E1,2, Pavia- ... Clear cell renal cell carcinoma (ccRCC) is characterized by inactivation of the von Hippel-Lindau tumour suppressor gene (VHL ... Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. [Eur Urol. 2017] ... Re: Targeting Renal Cell Carcinoma with a HIF-2 Antagonist. [Eur Urol. 2018] ...
... treatment and resreatch studies about kidney and renal cell carcinoma for the medical professionals while caring for their ... The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate ... Renal and Urology News Return To Top Renal & Urology News publishes timely news coverage of scientific developments of interest ... Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo ...
Gain a better understanding of cystic renal cell carcinoma and the best approaches to diagnosing and managing this uncommon ... Table 2. The character of cystic renal cell carcinoma concurrent renal cell carcinomas Pt. No.. Age (yr). Sex. Mass location ( ... Cystic renal cell carcinoma (CRCC) is relatively rare; it represents a special subtype of renal cell carcinoma (RCC) associated ... Cystic Renal Cell Carcinoma. A Report of 67 Cases Including 4 Cases With Concurrent Renal Cell Carcinoma. ...
Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney. ... Renal cell carcinoma is the most common type of kidney cancer in adults. It occurs most often in men 60 to 70 years old. ... Renal cell carcinoma is a type of kidney cancer that starts in the lining of very small tubes (tubules) in the kidney. ... Renal cell cancer treatment (PDQ) -- health professional version. www.cancer.gov/types/kidney/hp/kidney-treatment-pdq. Updated ...
Renal cell carcinoma is responsible for about 90 percent of kidney cancers in adults. Renal cell carcinoma appears to be caused ... Renal cell carcinoma, a disease arising from malignant epithelial cells in the kidneys. ... Renal cell carcinoma, a disease arising from malignant epithelial cells in the kidneys. Renal cell carcinoma is responsible for ... science/renal-cell-carcinoma", "shareUrl": "https://www.britannica.com/science/renal-cell-carcinoma", "title": "Renal cell ...
Renal cell carcinoma is rarely detected in the early stages of disease, since there are often no obvious symptoms until the ... Renal Cell Carcinoma Diagnosis. News-Medical, viewed 20 October 2020, https://www.news-medical.net/health/Renal-Cell-Carcinoma- ... Renal Cell Carcinoma Diagnosis. News-Medical. 20 October 2020. ,https://www.news-medical.net/health/Renal-Cell-Carcinoma- ... Renal Cell Carcinoma Diagnosis. News-Medical. https://www.news-medical.net/health/Renal-Cell-Carcinoma-Diagnosis.aspx. ( ...
Learn more about renal cell carcinoma, or kidney cancer, and treatment options, including targeted therapy, courtesy of ... About renal cell carcinoma. Renal cell carcinoma, or RCC, develops in the lining of the kidneys tubes and grows into a mass or ... Treating renal cell carcinoma. Treatment plans for patients with advanced renal cell carcinoma (RCC) vary, but can often ... Become an ally in the fight against renal cell carcinoma. Visit www.AlliesinRCC.com to learn more about RCC. ...
Renal cell carcinoma occurs when cancer cells form in the tubules of the kidneys. Find out about the risks, symptoms, ... More in Fight for the Future with Renal Cell Carcinoma. *. 7 Tips to Stay on Track with Your At-Home Renal Cell Carcinoma Care ... Renal cell carcinoma, or RCC, is also called hypernephroma, adenocarcinoma of renal cells, or renal or kidney cancer. Learn the ... Renal cell carcinoma is the most common form of kidney cancer. But not all renal cell cancers are the same. Learn about the ...
Renal cell carcinoma (RCC) is a type of kidney cancer. Often, RCC has no initial symptoms. When symptoms and signs appear they ... Renal cell cancer (also termed renal cell carcinoma or RCC) is a disease that occurs when certain kidney cells become malignant ... Types of renal cell carcinoma. The subtypes of RCC are mainly based on their microscopic appearance. The most common type is ... Treatment of renal cell carcinoma. The treatment of kidney cancer is often decided by the patient and physician and is based on ...
Cite this: FDA Approves Cabozantinib for Renal Cell Carcinoma - Medscape - Apr 26, 2016. ... for the treatment of patients with advanced renal cell carcinoma (RCC) who have received previous antiangiogenic therapy. ... Treatment of Anemia in Patients With Renal Disease Reviewed * Risk of Kidney-cancer Recurrence Persists Beyond 5 Years After ...
Diagnosed with renal cell carcinoma at just 30, Lisa Velasquez is celebrating her 10th year of remission. Learn more about ... She was diagnosed with renal cell carcinoma (RCC) when she was just 30. ... I kept thinking about a dear friends father who had been diagnosed with renal cancer and died six months later. ...
Renal cell carcinoma (see the image below) is the most common type of kidney cancer in adults. It accounts for approximately 3 ... Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these ... encoded search term (Renal%20Cell%20Carcinoma) and Renal Cell Carcinoma What to Read Next on Medscape. Medscape Consult. ... Renal cell carcinoma (RCC) is a diagnostic consideration when a renal mass is found on a radiologic study. In 25-30% of cases, ...
Latest Renal Cell Carcinoma Meetings * No recent meetings in Renal Cell Carcinoma ... Clinical Focus In Renal Cell Carcinoma: Clues from Gene Studies Mutations in four genes appear to play a key role in the origin ... Clinical Focus in Renal Cell Carcinoma: Indolent Disease Tx Initial observation and intermittent therapy might be options for ... VIENNA -- Metastatic renal cell carcinoma responded about as well to the oral targeted agent pazopanib (Votrient) as to oral ...
Renal cell carcinoma is the 14th most common cancer worldwide, with the highest incidence rates in North America, Europe, and ... better preserves renal parenchymal volume (which correlates with overall renal function), reduces recovery time, and can result ... finds that ablative techniques have widened the range of treatment options available to patients with renal cell carcinoma.. ... the advent of ablative techniques has widened the range of treatment options available to patients with renal cell carcinoma ( ...
Renal amyloidosis associated with gastric carcinoma. Br Med J 1968; 1 :99 ... Renal amyloidosis associated with gastric carcinoma.. Br Med J 1968; 1 doi: https://doi.org/10.1136/bmj.1.5584.99 (Published 13 ...
... Mohammad Kazem Moslemi,1 Shabir Al-Mousawi,2 and Mohammad Hasan Dehghani ... Mohammad Kazem Moslemi, and Mehdi Abedinzadeh, "Chronic headache as the first symptom of an undiagnosed renal cell carcinoma," ...
... Takeshi Azuma, Yukihide Matayoshi, Yohsuke Sato, Yujiro Sato, and Yasushi ... I. N. Zama, T. E. Hutson, P. Elson et al., "Sunitinib rechallenge in metastatic renal cell carcinoma patients," Cancer, vol. ... Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). A case of a ... C. Porta, G. Tortora, C. Linassier et al., "Maximising the duration of disease control in metastatic renal cell carcinoma with ...
Advanced Renal Cell Carcinoma (RCC) cannot be cured by surgery alone. Its resillience to irradiation and chemotherapy demands a ... Clinical Relevance of Proliferation Rates in Renal Cell Carcinoma W. de Riese, E. P. Allhoff, C. G. Stief, R. Schlick, P. Anton ... Advanced Renal Cell Carcinoma (RCC) cannot be cured by surgery alone. Its resillience to irradiation and chemotherapy demands a ... Cell Proliferation and Cellular Heterogeneity in Renal Cell Carcinoma. * Front Matter Pages 35-35 ...
Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining of the proximal ... Renal Cell Carcinoma Epidemiology. Read More Renal Cell Carcinoma Symptoms. Read More Renal Cell Carcinoma Diagnosis. Read More ... What is Renal Cell Carcinoma? Renal cell carcinoma, also called hypernephroma, is a cancer of the kidneys that forms in the ... Renal Cell Carcinoma. Renal cell carcinoma (RCC, also known as hypernephroma) is a kidney cancer that originates in the lining ...
Renal cell carcinoma, NOS, Renal Cell Cancer, Renal Cell Carcinoma, Renal Cell Carcinoma, Stage Unspecified, Renal Cell ... renal cell carcinoma renal carcinoma that has material basis in the lining of the proximal convoluted renal tubule of the ... renal cell carcinoma (en); سرطانة الخلية الكلوية (ar); 肾细胞癌 (zh-hans); Rak bubrega (bs) renal carcinoma that has material basis ... Carcinoma delle cellule renali, Carcinoma renale (it); Grawitz腫瘍, グラヴィッツ腫瘍 (ja); néphrocarcinome (fr); Renal cell carcinoma, ...
Tag: renal carcinoma. CancerDiagnostic tests & procedures. Kidney Cancer and Incidentalomas. Kidney cancer diagnoses are ...
... (RCC) is curable only in patients presenting with resectable, early-stage disease. Advanced local or ... Renal arteriograms are occasionally still performed during evaluation of a solid renal mass. Renal-cell carcinoma ... Swanson DA, Wallace S: Surgery of metastatic renal cell carcinoma and use of renal infarction. Semin Surg Oncol 4:124â 128, ... Bracken RB, Johnson DE, Goldstein HM, et al: Percutaneous transfemoral renal artery occlusion in patients with renal carcinoma ...
... , Kidney Cancer, Renal Cancer, Renal Cell Adenocarcinoma, Clear Cell Adenocarcinoma of Kidney, Papillary ... Renal cell carcinoma NOS, renal cell carcinoma (diagnosis), renal cell carcinoma, renal adenocarcinoma, Carcinoma, Renal Cell [ ... Renal Cell Adenocarcinomas, Renal Cell Carcinomas, RENAL CELL CARCINOMA, Renal cell carcinoma-morpholog, Renal carcinoma, ... Renal Cell Carcinoma. Renal Cell Carcinoma Aka: Renal Cell Carcinoma, Kidney Cancer, Renal Cancer, Renal Cell Adenocarcinoma, ...
Sorafenib in advanced clear-cell renal-cell carcinoma.. Escudier B1, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, ... What are the indications for sorafenib treatment in patients with renal cell carcinoma? [Nat Clin Pract Oncol. 2007] ... From November 2003 to March 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to standard ... Renal-cell carcinoma--molecular pathways and therapies. [N Engl J Med. 2007] ...
Variant of renal cell carcMetastaticMedullary carcinomaTreat renal cell carcRisk of developing renaPapillary2017KidneysSunitinibAdenocarcinomaSubtypesSarcomatoidIncidenceEpithelialGlobal Renal Cell CarcBlood in thSymptoms of renal cell carcManagement of renal cell carcEpidemiologyOutcomesPrimary renal cell carcPrognosisSubtype of renal cell carcDiagnosis and managementCell carcinoma therapeuticsTreatmentTransitional cell carcMetastasis of renal cell
- The safety and efficacy of nivolumab for treating metastatic renal cell carcinoma is comparable to that found in the CheckMate 025 trial. (renalandurologynews.com)
- Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not. (renalandurologynews.com)
- Immunotherapy with atezolizumab plus targeted therapy with bevacizumab improves progression-free survival better than sunitinib in patients with untreated metastatic renal cell carcinoma. (renalandurologynews.com)
- Excruciating, sharp, bandlike back pain may be an early warning for spinal cord compression due to metastatic renal cell carcinoma and should not be ignored. (medscape.com)
- Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. (medscape.com)
- Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. (medscape.com)
- More than 80% of patients with metastatic renal cell carcinoma remained alive without disease progression 3 years after image-guided local ablation of tumors, a retrospective study showed. (medpagetoday.com)
- A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials. (medpagetoday.com)
- Two small-molecule inhibitors proved comparable as first-line therapy for metastatic renal-cell carcinoma (RCC), results of a large randomized trial showed. (medpagetoday.com)
- SILVER SPRING, Md. -- An FDA advisory committee voiced near unanimous disapproval for a novel advanced renal cell carcinoma drug and a drug-device combo to treat unresectable ocular melanoma that is metastatic to the liver. (medpagetoday.com)
- Metastatic growth of renal cell carcinoma did not increase after completion of treatment with sunitinib (Sutent), alleviating concerns that had arisen in recent animal studies, an analysis of trial findings showed. (medpagetoday.com)
- VIENNA -- Metastatic renal cell carcinoma responded about as well to the oral targeted agent pazopanib (Votrient) as to oral sunitinib (Sutent), researchers said here. (medpagetoday.com)
- Several molecular targeted agents have been approved for clinical use for metastatic renal cell carcinoma (mRCC). (hindawi.com)
- Recently new molecular targeted agents were approved for metastatic renal cell carcinoma (mRCC) [ 1 ]. (hindawi.com)
- Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma. (news-medical.net)
- Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease. (news-medical.net)
- This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. (clinicaltrials.gov)
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are safe and effective after treatment with a programmed cell death 1 (PD-1) inhibitor in patients with metastatic renal cell carcinoma. (medworm.com)
- For many patients diagnosed with metastatic renal cell carcinoma, sunitinib alone is not inferior to surgery followed by sunitinib. (cancernetwork.com)
- The median survival for patients with metastatic disease from renal cell carcinoma is 13 months, but, in patients with gastric metastasis, the clinical course appears to be unpredictable, and they could die within a few weeks because of the high frequency of concomitant tumour involvement of other organs (5). (isciii.es)
- 3. Pollheimer MJ, Hinterleitner T A, Pollheimer VS, Schlemmer A, Langner C. Renal cell carcinoma metastatic to the stomach: single-centre experience and literature review. (isciii.es)
- Unusual gastric and pancreatic metastatic renal cell carcinoma presentation 10 years after surgery and immunotherapy: A case report and a review of literature. (isciii.es)
- Renal cell carcinoma (kidney cancer) is among the 10 most common cancers in both men and women, with 15-25 percent of patients having metastatic renal cell carcinoma (mRCC) where the cancer has spread to other parts of the body. (accc-cancer.org)
- Choueiri, T.K. & Motzer, R.J. Systemic therapy for metastatic renal-cell carcinoma. (nature.com)
- MIAMI - An analysis of patients with metastatic renal cell carcinoma treated during the targeted therapy era showed those with private insurance survived significantly longer than those with no insurance or government insurance, according to study results presented at International Kidney Cancer Symposium. (healio.com)
- This survival disparity was more significant [among] patients aged younger than 65 years, suggesting insurance status determined access to metastatic renal cell carcinoma treatment," Yu-Wei Chen, MD, MS, of Cleveland Clinic Taussig Cancer Institute, and colleagues wrote. (healio.com)
- Treatment costs for metastatic renal cell carcinoma have increased with the development of targeted therapy, and this may affect access to care, according to study background. (healio.com)
- Chen and colleagues assessed the effect of insurance status on receipt of treatment and survival among patients with metastatic renal cell carcinoma. (healio.com)
- Researchers used the National Cancer Data Base to identify patients diagnosed with metastatic renal cell carcinoma from 2006 to 2013. (healio.com)
- The association between insurance status and survival in metastatic renal cell carcinoma in the United States. (healio.com)
- My husband has metastatic renal? (drugs.com)
- What are the side effects of chemotherapy when you get it to treat metastatic renal cell carcinoma? (webmd.com)
- This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. (clinicaltrials.gov)
- The study included patients across International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk groups. (prnewswire.com)
- Incidence, mortality, and the incidence of metastatic disease at first presentation for cancer of the kidney and renal pelvis. (aafp.org)
- Despite the approval of several targeted therapies by entities such as the Food and Drug Administration, the European Medicines Agency and the Pharmaceuticals and Medical Devices Agency, the survival rate among patients with metastatic renal cell carcinoma has plateaued. (curetoday.com)
- We present a case of sarcomatoid renal cell carcinoma with multiple sclerotic skeletal metastatic lesions. (semanticscholar.org)
- Renal medullary carcinoma (RMC) is a rare, highly aggressive tumor recognized as an independent pathological entity. (urotoday.com)
- I started searching the Internet for stories of people who also had renal medullary carcinoma. (mdanderson.org)
- I started by creating a website, followed by a couple of Facebook, Twitter and Instagram pages, all of which were devoted to patients with renal medullary carcinoma. (mdanderson.org)
- I also have become an advocate for renal medullary carcinoma by creating awareness. (mdanderson.org)
- Renal medullary carcinoma has been termed "the seventh sickle cell nephropathy" because it is found almost exclusively in individuals with sickle cell trait or occasionally in those with sickle cell disease. (wikipedia.org)
- The etiology of renal medullary carcinoma is still not completely understood. (wikipedia.org)
- The other genetic or environmental factors that contribute to the risk of renal medullary carcinoma are unknown. (wikipedia.org)
- The diagnosis of renal medullary carcinoma is typically made after individuals with sickle cell trait present with the typical signs and symptoms outlined above, in combination with radiographic imaging (usually abdominal/pelvic CT scan) studies and ultimately surgical biopsy and pathological examination of the tumor. (wikipedia.org)
- As of 2009, there have been approximately 120 reported cases of renal medullary carcinoma. (wikipedia.org)
- Renal medullary carcinoma was first described as a clinicopathologic entity in 1995. (wikipedia.org)
- According to a study by NCBI named "Racial Disparity in Renal Cell Carcinoma Patient Survival according to Demographic and Clinical Characteristics" published in 2012, the African population runs a comparatively higher risk of developing renal cell carcinoma. (sbwire.com)
- Researchers found that people who ate lots of fruits and vegetables - more than 75 servings per month, or roughly three servings total per day - had the lowest risk of developing renal cell carcinoma. (medworm.com)
- The most frequent histological subtypes include clear cell renal cell carcinomas (ccRCC), papillary renal cell carcinomas (pRCC), and chromophobe renal cell carcinomas (crRCC) ( Figure 1 ). (scielo.br)
- Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. (aacrjournals.org)
- Although common RCC and papillary RCC both are derived from the same part of the renal tubule and have a similar antigenic phenotype, they differ in genetic changes. (atlasgeneticsoncology.org)
- Papillary RCC can be devided in adenomas and carcinomas. (atlasgeneticsoncology.org)
- Renal Cell Carcinoma Pipeline Analysis Report: 2017 includes list of pipeline of drugs in clinical development, and pipeline analysis by phase, indication sub-type, molecule type and company. (reportlinker.com)
- According to this research, the total diagnosed incident cases of Advanced Renal Cell Carcinoma in the G8 countries were 69,429 in 2017. (researchandmarkets.com)
- Renal cell carcinoma , a disease arising from malignant epithelial cells in the kidneys . (britannica.com)
- Over 90 percent of kidney cancers are renal cell carcinomas (RCC), which start in the tubules of the kidneys. (healthline.com)
- Renal carcinoma is a malignant formation formed in one or both kidneys. (rxmed.com)
- Analysis from a phase III trial confirmed the prognostic value of a 16-gene recurrence score in patients with high-risk renal cell carcinoma undergoing adjuvant sunitinib therapy. (cancernetwork.com)
- The FDA based this decision on data from 847 intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma from the randomized open-label CheckMate-214 trial, which compared the combination of nivolumab (Opdivo, Bristol-Myers Squibb) and ipilimumab (Yervoy, Bristol-Myers Squibb) with sunitinib (Sutent, Pfizer). (healio.com)
- As the first treatment option to increase OS for subgroups of patients with advanced renal cell carcinoma compared to sunitinib, the Opdivo plus low-dose Yervoy combination helps deliver on that promise," Johanna Mercier, head of U.S. Commercial at Bristol-Myers Squibb, said in the press release. (healio.com)
- Go to Clear Cell Renal Cell Carcinoma and Sarcomatoid and Rhabdoid Renal Cell Carcinoma for complete information on these topics. (medscape.com)
- Sarcomatoid renal cell carcinoma (SRCC) is an aggressive variant of renal cell carcinoma. (semanticscholar.org)
- Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition. (semanticscholar.org)
- Sarcomatoid renal cell carcinoma presenting in the oropharynx. (semanticscholar.org)
- Four cases of sarcomatoid renal cell carcinoma]. (semanticscholar.org)
- We herein report four cases of sarcomatoid renal cell carcinoma. (semanticscholar.org)
- Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. (semanticscholar.org)
- A case of sarcomatoid renal cell carcinoma is reported with light, immunohistochemical and electron microscopic findings. (semanticscholar.org)
- Renal sarcoma and sarcomatoid renal cell carcinoma: CT and angiographic features. (semanticscholar.org)
- The rising incidence of renal cell carcinoma and comparative lack of availability of effective therapies available point toward the scope of this market. (sbwire.com)
- North America and Europe dominated the global market due to unhealthy lifestyles, obesity, and hypertension in these regions and excessive smoking in the U.S. Asia and South America exhibit minimal incidence of renal cell carcinoma. (sbwire.com)
- The age-adjusted incidence of renal cell carcinoma has been rising by 3 percent per year. (reportlinker.com)
- This review provides an overview of the incidence of renal cell carcinoma (RCC) and a summary of the most commonly associated risk factors. (dovepress.com)
- An increased incidence of RCC has been associated with end-stage renal disease and with acquired cystic kidney disease. (atlasgeneticsoncology.org)
- The global renal cell carcinoma drugs market is anticipated to cross US$ 4.3 Billion mark by 2021. (medindia.net)
- Sutent accounts for largest share of the global renal cell carcinoma drugs market in 2015, while, Votrient is projected to witness the strongest growth during the forecasting period. (medindia.net)
- Global Renal Cell Carcinoma - Diagnosed Incident Cases to 2023 (8 Countries Covered)4. (medindia.net)
- Global Renal Cell Carcinoma - Major Branded Drugs Product Profiles and Sales Analysis to 2021 (11 Brands Covered)6. (medindia.net)
- Global Renal Cell Carcinoma Drugs - Pipeline Analysis (18 Drugs Covered)7. (medindia.net)
- The report will help in developing business strategies by understanding the trends shaping and driving the global Renal cell carcinoma market. (beforeitsnews.com)
- Identifying prevalent patient populations as well as risk factors in the global Renal cell carcinoma market will help to improve product design, pricing, and launch plans. (beforeitsnews.com)
- Advanced Renal Cell Carcinoma Epidemiology Forecast - 2028' report delivers an in - depth understanding of the disease, historical & forecasted epidemiology of Advanced Renal Cell Carcinoma in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), Japan and China. (researchandmarkets.com)
- The report provides the segmentation of the disease epidemiology by type - specific cases and severity specific cases of Advanced Renal Cell Carcinoma in the G8 countries. (researchandmarkets.com)
- The Report "Renal cell carcinoma - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Renal cell carcinoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). (beforeitsnews.com)
- It includes 10 years epidemiology historical and forecasted data of Renal cell carcinoma prevalent or incident cases segmented by age, sex and subpopulations. (beforeitsnews.com)
- In spite of advances in all fields of medical science, the prognosis of renal cell carcinoma has not improved during the last 25 years. (springer.com)
- Generally, the earlier the renal cell carcinoma is found, the better the prognosis. (cancertutor.com)
- Seventy-five percent to 80% of patients with advanced renal cell carcinoma have intermediate- or poor-risk disease, which historically is associated with a poor prognosis. (healio.com)
- iGATE RESEARCH report entitled "Renal Cell Carcinoma - Global Drugs Market Forecast and Pipeline Analysis to 2021" provides a comprehensive analysis of the fast-evolving high growth renal cell carcinoma therapeutics market. (medindia.net)
- Organize sales and marketing efforts by identifying the best opportunities for Renal cell carcinoma therapeutics in each of the markets covered. (beforeitsnews.com)
- In a phase Ib study, dual therapy with axitinib and pembrolizumab was well tolerated and demonstrated antitumor activity in treatment-naïve patients with advanced renal cell carcinoma. (renalandurologynews.com)
- Treatment plans for patients with advanced renal cell carcinoma (RCC) vary, but can often involve both surgery and medicine, and it is not uncommon for patients to be treated with more than one medicine or type of therapy. (novartis.com)
- The US Food and Drug Administration (FDA) has approved the oral therapy cabozantinib ( Cabometyx , Exelixis) for the treatment of patients with advanced renal cell carcinoma (RCC) who have received previous antiangiogenic therapy. (medscape.com)
- Advances in the treatment of renal disease. (medscape.com)
- The FDA has rejected the oral VEGF receptor tyrosine kinase inhibitor tivozanib, intended for the treatment of renal cell carcinoma, according to the drug's developer. (medpagetoday.com)
- Research finds that ablative techniques have widened the range of treatment options available to patients with renal cell carcinoma. (prweb.com)
- Research published in the October issue of the American Journal of Roentgenology finds that the advent of ablative techniques has widened the range of treatment options available to patients with renal cell carcinoma (RCC). (prweb.com)
- What are the indications for sorafenib treatment in patients with renal cell carcinoma? (nih.gov)
- On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). (fda.gov)
- Current results from treatment of renal cell carcinoma," 7th Proc. (springer.com)
- This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. (nih.gov)
- A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. (nih.gov)
- Many big pharma companies are working in developing drugs for the treatment of renal cell carcinoma. (reportlinker.com)
- This CME, CNE, and CPE-accredited educational program is designed to provide all members of the multidisciplinary care team knowledge and resources to successfully address practical issues and barriers faced in integration of immunotherapies into the treatment of renal cell carcinoma (RCC). (accc-cancer.org)
- The purpose of this meeting is to educate urologists, oncologists, NPs and PAs on the evolving treatment landscape for advanced renal cell carcinoma. (regonline.com)
- Checkpoint inhibitors for the treatment of renal cell carcinoma. (nature.com)
- Diagnostic confirmation of bladder carcinoma via cystoscopy and biopsy is critical to determining ultimate treatment algorithm. (renalandurologynews.com)
- The FDA today approved the combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma. (healio.com)
- We retrospectively collected the data of 5378 patients who were surgically treated for RCC in 16 academic centres involved in the Surveillance and Treatment Update Renal Neoplasms (SATURN) project. (wiley.com)
- The report covers the detailed overview of Advanced Renal Cell Carcinoma explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns. (researchandmarkets.com)
- The major drugs used for the treatment of renal cell carcinoma include Sutent, Nexavar, Votrient, Avastin and Inyta amongst others. (medindia.net)
- The most recent drugs approved for the treatment of renal cell carcinoma is Bristol-Myers Squibb's Opdivo. (medindia.net)
- The treatment of renal cell carcinoma is based on several common methods used alone or in a complex manner. (rxmed.com)
- PFE ) today announced that the European Commission (EC) has approved BAVENCIO ® (avelumab) in combination with axitinib for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (prnewswire.com)
- Renal cell carcinoma is characterized by susceptibility to both immunotherapeutic and antiangiogenic treatment approaches and resistance to cytotoxic chemotherapy," they wrote. (curetoday.com)